Company research
Loading SEC business and financials…
AI relationship research has not yet been verified for this company.
Listing data synced 2026-04-16.
Loading your outlook…
Loading…
Loading company activity...
Estimated market cap
Unavailable
A supported share count and cached closing price are required.
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. We have five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector.
Excerpt from Item 1 — Business; filed 2026-03-19. May be shortened.
Source: SEC Company Facts. Checked 2026-10-01. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
